A citation-based method for searching scientific literature

Michel Attal, Valerie Lauwers-Cances, Cyrille Hulin, Xavier Leleu, Denis Caillot, Martine Escoffre, Bertrand Arnulf, Margaret Macro, Karim Belhadj, Laurent Garderet, Murielle Roussel, Catherine Payen, Claire Mathiot, Jean P Fermand, Nathalie Meuleman, Sandrine Rollet, Michelle E Maglio, Andrea A Zeytoonjian, Edie A Weller, Nikhil Munshi, Kenneth C Anderson, Paul G Richardson, Thierry Facon, Hervé Avet-Loiseau, Jean-Luc Harousseau, Philippe Moreau. N Engl J Med 2017
Times Cited: 619







List of co-cited articles
678 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Philippe Moreau, Michel Attal, Cyrille Hulin, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C Béné, Annemiek Broijl, Hélène Caillon, Denis Caillot,[...]. Lancet 2019
423
36

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Shaji Kumar, Bruno Paiva, Kenneth C Anderson, Brian Durie, Ola Landgren, Philippe Moreau, Nikhil Munshi, Sagar Lonial, Joan Bladé, Maria-Victoria Mateos,[...]. Lancet Oncol 2016
35

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Peter M Voorhees, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J Costa, Larry D Anderson,[...]. Blood 2020
230
34

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Thierry Facon, Shaji Kumar, Torben Plesner, Robert Z Orlowski, Philippe Moreau, Nizar Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach,[...]. N Engl J Med 2019
464
30


Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Brian G M Durie, Antje Hoering, Muneer H Abidi, S Vincent Rajkumar, Joshua Epstein, Stephen P Kahanic, Mohan Thakuri, Frederic Reu, Christopher M Reynolds, Rachael Sexton,[...]. Lancet 2017
492
28

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
Philip L McCarthy, Sarah A Holstein, Maria Teresa Petrucci, Paul G Richardson, Cyrille Hulin, Patrizia Tosi, Sara Bringhen, Pellegrino Musto, Kenneth C Anderson, Denis Caillot,[...]. J Clin Oncol 2017
350
27

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Shaji K Kumar, Susanna J Jacobus, Adam D Cohen, Matthias Weiss, Natalie Callander, Avina K Singh, Terri L Parker, Alexander Menter, Xuezhong Yang, Benjamin Parsons,[...]. Lancet Oncol 2020
87
26

Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
Nisha S Joseph, Jonathan L Kaufman, Madhav V Dhodapkar, Craig C Hofmeister, Dhwani K Almaula, Leonard T Heffner, Vikas A Gupta, Lawrence H Boise, Sagar Lonial, Ajay K Nooka. J Clin Oncol 2020
76
27

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.
Laura Rosiñol, Albert Oriol, Rafael Rios, Anna Sureda, María Jesús Blanchard, Miguel Teodoro Hernández, Rafael Martínez-Martínez, Jose M Moraleda, Isidro Jarque, Juan Bargay,[...]. Blood 2019
104
20

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
Aurore Perrot, Valerie Lauwers-Cances, Jill Corre, Nelly Robillard, Cyrille Hulin, Marie-Lorraine Chretien, Thomas Dejoie, Sabrina Maheo, Anne-Marie Stoppa, Brigitte Pegourie,[...]. Blood 2018
207
20

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
María-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lucio, Zsolt Nagy, Polina Kaplan,[...]. N Engl J Med 2018
570
19

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
J Anthony Child, Gareth J Morgan, Faith E Davies, Roger G Owen, Susan E Bell, Kim Hawkins, Julia Brown, Mark T Drayson, Peter J Selby. N Engl J Med 2003
18

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.
Edward A Stadtmauer, Marcelo C Pasquini, Beth Blackwell, Parameswaran Hari, Asad Bashey, Steven Devine, Yvonne Efebera, Siddharta Ganguly, Cristina Gasparetto, Nancy Geller,[...]. J Clin Oncol 2019
123
17

Autologous transplantation and maintenance therapy in multiple myeloma.
Antonio Palumbo, Federica Cavallo, Francesca Gay, Francesco Di Raimondo, Dina Ben Yehuda, Maria Teresa Petrucci, Sara Pezzatti, Tommaso Caravita, Chiara Cerrato, Elena Ribakovsky,[...]. N Engl J Med 2014
522
16

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
Antonio Palumbo, Hervé Avet-Loiseau, Stefania Oliva, Henk M Lokhorst, Hartmut Goldschmidt, Laura Rosinol, Paul Richardson, Simona Caltagirone, Juan José Lahuerta, Thierry Facon,[...]. J Clin Oncol 2015
979
16

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
M Attal, J L Harousseau, A M Stoppa, J J Sotto, J G Fuzibet, J F Rossi, P Casassus, H Maisonneuve, T Facon, N Ifrah,[...]. N Engl J Med 1996
16

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.
Philippe Moreau, Cyrille Hulin, Margaret Macro, Denis Caillot, Carine Chaleteix, Murielle Roussel, Laurent Garderet, Bruno Royer, Sabine Brechignac, Mourad Tiab,[...]. Blood 2016
167
16

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Nikhil C Munshi, Larry D Anderson, Nina Shah, Deepu Madduri, Jesús Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, David Siegel, Albert Oriol,[...]. N Engl J Med 2021
380
16

International staging system for multiple myeloma.
Philip R Greipp, Jesus San Miguel, Brian G M Durie, John J Crowley, Bart Barlogie, Joan Bladé, Mario Boccadoro, J Anthony Child, Herve Avet-Loiseau, Robert A Kyle,[...]. J Clin Oncol 2005
15

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.
Nikhil C Munshi, Herve Avet-Loiseau, Andy C Rawstron, Roger G Owen, J Anthony Child, Anjan Thakurta, Paul Sherrington, Mehmet Kemal Samur, Anna Georgieva, Kenneth C Anderson,[...]. JAMA Oncol 2017
289
15

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Meletios A Dimopoulos, Albert Oriol, Hareth Nahi, Jesus San-Miguel, Nizar J Bahlis, Saad Z Usmani, Neil Rabin, Robert Z Orlowski, Mieczyslaw Komarnicki, Kenshi Suzuki,[...]. N Engl J Med 2016
920
15

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Noopur Raje, Jesus Berdeja, Yi Lin, David Siegel, Sundar Jagannath, Deepu Madduri, Michaela Liedtke, Jacalyn Rosenblatt, Marcela V Maus, Ashley Turka,[...]. N Engl J Med 2019
719
15

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
Brian G M Durie, Antje Hoering, Rachael Sexton, Muneer H Abidi, Joshua Epstein, S Vincent Rajkumar, Angela Dispenzieri, Stephen P Kahanic, Mohan C Thakuri, Frederic J Reu,[...]. Blood Cancer J 2020
76
19

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Michel Attal, Paul G Richardson, S Vincent Rajkumar, Jesus San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A Dimopoulos,[...]. Lancet 2019
277
15

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Sagar Lonial, Hans C Lee, Ashraf Badros, Suzanne Trudel, Ajay K Nooka, Ajai Chari, Al-Ola Abdallah, Natalie Callander, Nikoletta Lendvai, Douglas Sborov,[...]. Lancet Oncol 2020
311
15


Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Antonio Palumbo, Asher Chanan-Khan, Katja Weisel, Ajay K Nooka, Tamas Masszi, Meral Beksac, Ivan Spicka, Vania Hungria, Markus Munder, Maria V Mateos,[...]. N Engl J Med 2016
925
14

Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Michel Attal, Valerie Lauwers-Cances, Gerald Marit, Denis Caillot, Philippe Moreau, Thierry Facon, Anne Marie Stoppa, Cyrille Hulin, Lofti Benboubker, Laurent Garderet,[...]. N Engl J Med 2012
793
14

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Ajai Chari, Dan T Vogl, Maria Gavriatopoulou, Ajay K Nooka, Andrew J Yee, Carol A Huff, Philippe Moreau, David Dingli, Craig Cole, Sagar Lonial,[...]. N Engl J Med 2019
288
14

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Pieter Sonneveld, Hervé Avet-Loiseau, Sagar Lonial, Saad Usmani, David Siegel, Kenneth C Anderson, Wee-Joo Chng, Philippe Moreau, Michel Attal, Robert A Kyle,[...]. Blood 2016
471
13

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S Vincent Rajkumar, Meletios A Dimopoulos, Antonio Palumbo, Joan Blade, Giampaolo Merlini, María-Victoria Mateos, Shaji Kumar, Jens Hillengass, Efstathios Kastritis, Paul Richardson,[...]. Lancet Oncol 2014
13

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
A Keith Stewart, S Vincent Rajkumar, Meletios A Dimopoulos, Tamás Masszi, Ivan Špička, Albert Oriol, Roman Hájek, Laura Rosiñol, David S Siegel, Georgi G Mihaylov,[...]. N Engl J Med 2015
912
13

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Philippe Moreau, Tamás Masszi, Norbert Grzasko, Nizar J Bahlis, Markus Hansson, Ludek Pour, Irwindeep Sandhu, Peter Ganly, Bartrum W Baker, Sharon R Jackson,[...]. N Engl J Med 2016
653
13

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Jesus G Berdeja, Deepu Madduri, Saad Z Usmani, Andrzej Jakubowiak, Mounzer Agha, Adam D Cohen, A Keith Stewart, Parameswaran Hari, Myo Htut, Alexander Lesokhin,[...]. Lancet 2021
171
13

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Graham H Jackson, Faith E Davies, Charlotte Pawlyn, David A Cairns, Alina Striha, Corinne Collett, Anna Hockaday, John R Jones, Bhuvan Kishore, Mamta Garg,[...]. Lancet Oncol 2019
170
12

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Lotfi Benboubker, Meletios A Dimopoulos, Angela Dispenzieri, John Catalano, Andrew R Belch, Michele Cavo, Antonello Pinto, Katja Weisel, Heinz Ludwig, Nizar Bahlis,[...]. N Engl J Med 2014
549
12

Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.
Binod Dhakal, Aniko Szabo, Saurabh Chhabra, Mehdi Hamadani, Anita D'Souza, Saad Z Usmani, Rita Sieracki, Bishal Gyawali, Jeffrey L Jackson, Fotis Asimakopoulos,[...]. JAMA Oncol 2018
86
13

Lenalidomide after stem-cell transplantation for multiple myeloma.
Philip L McCarthy, Kouros Owzar, Craig C Hofmeister, David D Hurd, Hani Hassoun, Paul G Richardson, Sergio Giralt, Edward A Stadtmauer, Daniel J Weisdorf, Ravi Vij,[...]. N Engl J Med 2012
787
12

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Michele Cavo, Paola Tacchetti, Francesca Patriarca, Maria Teresa Petrucci, Lucia Pantani, Monica Galli, Francesco Di Raimondo, Claudia Crippa, Elena Zamagni, Antonio Palumbo,[...]. Lancet 2010
651
12

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Sagar Lonial, Meletios Dimopoulos, Antonio Palumbo, Darrell White, Sebastian Grosicki, Ivan Spicka, Adam Walter-Croneck, Philippe Moreau, Maria-Victoria Mateos, Hila Magen,[...]. N Engl J Med 2015
912
12

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Meletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kenshi Suzuki, Marc S Raab,[...]. N Engl J Med 2018
283
12

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.
Nikhil C Munshi, Herve Avet-Loiseau, Kenneth C Anderson, Paola Neri, Bruno Paiva, Mehmet Samur, Meletios Dimopoulos, Margarita Kulakova, Annette Lam, Mahmoud Hashim,[...]. Blood Adv 2020
78
15

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Meletios Dimopoulos, Hang Quach, Maria-Victoria Mateos, Ola Landgren, Xavier Leleu, David Siegel, Katja Weisel, Hui Yang, Zandra Klippel, Anita Zahlten-Kumeli,[...]. Lancet 2020
168
12

International uniform response criteria for multiple myeloma.
B G M Durie, J-L Harousseau, J S Miguel, J Bladé, B Barlogie, K Anderson, M Gertz, M Dimopoulos, J Westin, P Sonneveld,[...]. Leukemia 2006
11

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.
Juan-Jose Lahuerta, Bruno Paiva, Maria-Belen Vidriales, Lourdes Cordón, Maria-Teresa Cedena, Noemi Puig, Joaquin Martinez-Lopez, Laura Rosiñol, Norma C Gutierrez, María-Luisa Martín-Ramos,[...]. J Clin Oncol 2017
169
11

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Paul G Richardson, Albert Oriol, Meral Beksac, Anna Marina Liberati, Monica Galli, Fredrik Schjesvold, Jindriska Lindsay, Katja Weisel, Darrell White, Thierry Facon,[...]. Lancet Oncol 2019
156
11

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Ola Landgren, Malin Hultcrantz, Benjamin Diamond, Alexander M Lesokhin, Sham Mailankody, Hani Hassoun, Carlyn Tan, Urvi A Shah, Sydney X Lu, Meghan Salcedo,[...]. JAMA Oncol 2021
30
36

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Ibai Goicoechea, Noemi Puig, Maria-Teresa Cedena, Leire Burgos, Lourdes Cordón, María-Belén Vidriales, Juan Flores-Montero, Norma C Gutierrez, Maria-Jose Calasanz, Maria-Luisa Martin Ramos,[...]. Blood 2021
42
26

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Paul G Richardson, Edie Weller, Sagar Lonial, Andrzej J Jakubowiak, Sundar Jagannath, Noopur S Raje, David E Avigan, Wanling Xie, Irene M Ghobrial, Robert L Schlossman,[...]. Blood 2010
665
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.